<unk>  is usually prescribed as a long-term treatment of angina pectoris, and in some countries (including France) for tinnitus and dizziness. It is taken twice a day. In 2012, the European Medicines Agency (EMA) finished a review of benefits and risks of<unk>  and recommended restricting use of<unk> -containing medicines to just as an additional treatment of angina pectoris in cases of inadequate control by or intolerance to first-line antianginal therapies. Controlled studies in angina patients have shown that<unk>  increases coronary flow reserve, thereby delaying the onset of ischemia associated with exercise, limits rapid swings in blood pressure without any significant variations in heart rate, significantly decreases the frequency of angina attacks, and leads to a significant decrease in the use of nitrates. However, there was a 2020 placebo-controlled, randomized trial assessed<unk>  in over 6000 patients who had recently had a coronary intervention or heart surgery.<unk>  was administered along with typical anti-anginal therapy versus typical anti-anginal therapy alone and no significant difference between the two groups with respect to cardiac death, hospital admission for a cardiac event, recurrence or persistence of angina, or the need for repeat coronary angiography was found. This study therefore calls into question the clinical utility of<unk>  in the treatment of angina. It improves left ventricular function in diabetic patients with coronary heart disease. Recently, it has been shown to be effective in patients with heart failure of different etiologies.
Trimetazidine
Esketamine
Eptazocine
Pentazocine
Etomidate
Bremazocine
Triethylenetetramine
Fentanyl